National Research Corporation Announces Quarterly Dividend and Stock Repurchase Authorization
May 20 2022 - 5:00PM
National Research Corporation, dba NRC Health (the “Company”),
(NASDAQ:NRC) announced that its Board of Directors has declared a
quarterly cash dividend of $0.24 (twenty-four cents) per share
payable Friday, July 15, 2022, to shareholders of record as of the
close of business on Thursday, June 30, 2022.
Also, on May 19, 2022, the Company’s Board of
Directors approved a new stock repurchase authorization of up to
2.5 million shares of its common stock. The Company is authorized
to repurchase from time-to-time shares of its outstanding common
stock on the open market or in privately negotiated transactions.
The timing and amount of stock repurchases will depend on a variety
of factors, including market conditions as well as corporate and
regulatory considerations. The stock repurchase authorization may
be suspended, modified, or discontinued at any time and the Company
has no obligation to repurchase any amount of its common stock in
connection with the repurchase authorization. The repurchase
authorization has no set expiration date. The new authorization
follows the Company’s recent repurchase of all shares remaining
under the Board’s previous repurchase authorization.
For more than 40 years, NRC Health has been
committed to achieving Human Understanding and bringing healthcare
organizations closer to their customers than ever before by
illuminating and improving the key moments that define an
experience and build trust. Guided by their uniquely empathic
heritage, proprietary methods, skilled associates, and holistic
approach, NRC Health helps its customers design experiences that
exceed expectations, inspire loyalty, and improve well-being among
patients, residents, physicians, nurses, and staff.
Kevin R. Karas
Chief Financial Officer
402-475-2525
National Research (NASDAQ:NRC)
Historical Stock Chart
From Jun 2024 to Jul 2024
National Research (NASDAQ:NRC)
Historical Stock Chart
From Jul 2023 to Jul 2024